UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average I	ourden					
hours per response	0.5					

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
Name and Address of Reporting Person* Curd John G				THE	2. Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below) President and CMO					
(Last) (First) (Middle) C/O THRESHOLD PHARMACEUTICALS, 1300 SEAPORT BLVD. SUITE 500					3. Date of Earliest Transaction (Month/Day/Year) 10/22/2007										Fresid	ent and Civio			
(Street) REDWOOD CITY, CA 94063				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)								_X_	6. Individual or Joint/Group FilingCheck Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqui								Acquired	uired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye		ear) Ex	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr	Transaction ode nstr. 8)		4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)		(D) Owr Tran	O) Owned Following I Transaction(s) (Instr. 3 and 4)		C F C o	wnership orm: rirect (D) r Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
			Table						tl c quired	his for urrent I, Dispo	m are ly vali	not required not required on the co	red to res ontrol nun cially Own	pond unles nber.		i contained ii i displays a	1 SEC	474 (9-02)	
1 771 0	l.,	la m	la. p	_ ` 0	, pu							ble securiti	т' —	4.4 .	lo p :	0.37 1 0	1.0	1,, ,,	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	version xercise (Month/Day/Year) e of vative	Date Execution Date, if		Code	Transaction Decay Code Se (Instr. 8) Ac or (D				6. Date Exercisal Expiration Date (Month/Day/Yea		te	and	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D or Indirect (I)	(Instr. 4)
				Code	v	(A)	(D	I	Date Exercis	sable	Ex Da	epiration ate	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock Option (right to buy) (1)	\$ 0.64	10/22/2007		A			470,0	000 1	10/22	/2008	(2) 10	0/21/2017	Commo	n 470,000	(3)	470,000	D		

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Curd John G C/O THRESHOLD PHARMACEUTICALS 1300 SEAPORT BLVD. SUITE 500 REDWOOD CITY, CA 94063			President and CMO				

Signatures

/s/ Harold E. Selick, Attorney-in-Fact	10/24/2007
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Stock Option was granted pursuant to the Threshold Pharmaceuticals, Inc. 2004 Amended and Restated Equity Incentive Plan.
- (2) 25% of the shares underlying the Option shall vest and become exercisable on October 22, 2008. Thereafter the remaining shares will vest and become exercisable at a rate of 1/48th per month.
- (3) Not Applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.